Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases
Alamar Biosciences and Nightingale Health have initiated a collaborative study with the UK Biobank to identify early blood biomarkers for neurodegenerative conditions, including Parkinson’s and Alzheimer’s disease. This project, named UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife, will analyze hundreds of proteins in 80,000 blood samples from UK Biobank participants. The study combines Alamar’s NULISA protein-detection technology, which can detect proteins at very low concentrations using antibodies and DNA-based signals, with Nightingale’s laboratory infrastructure and the UK Biobank’s extensive health data. The goal is to uncover early molecular signatures that could aid in predicting disease risk, improving diagnosis, and guiding future treatment strategies. The study is expected to conclude by the end of 2027, with the resulting data made accessible to approved researchers globally through the UK Biobank Research Analysis Platform.
